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7RESEARCH ARTICLE Open AccessCytomegalovirus infection and disease
reduce 10-year cardiac allograft
vasculopathy-free survival in heart
transplant recipients
Inger Johansson1*, Rune Andersson1, Vanda Friman1, Nedim Selimovic2, Lars Hanzen1, Salmir Nasic3,
Ulla Nyström2 and Vilborg Sigurdardottir4Abstract
Background: Cytomegalovirus (CMV) is associated with an increased risk of cardiac allograft vasculopathy (CAV),
the major limiting factor for long-term survival after heart transplantation (HTx). The purpose of this study was to
evaluate the impact of CMV infection during long-term follow-up after HTx.
Methods: A retrospective, single-centre study analyzed 226 HTx recipients (mean age 45 ± 13 years, 78 % men)
who underwent transplantation between January 1988 and December 2000. The incidence and risk factors for CMV
infection during the first year after transplantation were studied. Risk factors for CAV were included in an analyses
of CAV-free survival within 10 years post-transplant. The effect of CMV infection on the grade of CAV was analyzed.
Results: Survival to 10 years post-transplant was higher in patients with no CMV infection (69 %) compared with
patients with CMV disease (55 %; p = 0.018) or asymptomatic CMV infection (54 %; p = 0.053). CAV-free survival time
was higher in patients with no CMV infection (6.7 years; 95 % CI, 6.0–7.4) compared with CMV disease (4.2 years; CI,
3.2–5.2; p < 0.001) or asymptomatic CMV infection (5.4 years; CI, 4.3–6.4; p = 0.013). In univariate analysis, recipient
age, donor age, coronary artery disease (CAD), asymptomatic CMV infection and CMV disease were significantly
associated with CAV-free survival. In multivariate regression analysis, CMV disease, asymptomatic CMV infection, CAD
and donor age remained independent predictors of CAV-free survival at 10 years post-transplant.
Conclusions: CAV-free survival was significantly reduced in patients with CMV disease and asymptomatic CMV
infection compared to patients without CMV infection. These findings highlight the importance of close monitoring
of CMV viral load and appropriate therapeutic strategies for preventing asymptomatic CMV infection.
Keywords: Heart transplantation, CMV, Cardiac allograft vasculopathy, SurvivalBackground
Cardiac allograft vasculopathy (CAV) is a major limiting
factor for long-term survival following heart transplant-
ation (HTx) [1]. CAV is a complex, multifactorial process
with various immunological and non-immunological risk
factors, including older donor age, pre-transplant coronary
artery disease (CAD) and cardiovascular risk factors,
implicated in its pathogenesis [1–4].* Correspondence: inger.johansson@infect.gu.se
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(http://creativecommons.org/publicdomain/zeCytomegalovirus (CMV) infection may play an essential
role in CAV progression [5–7]. Following primary infec-
tion, CMV remains latent in CD 34+ bone marrow pro-
genitor cells and monocytes [8] Cytomegalovirus
reactivates frequently. The endothelial cell appears to
be a target for CMV. Evidence of a link between CMV
and CAV has been described [9–11], but other studies
have not confirmed these findings [12, 13]. The develop-
ment of CAV is initiated within the first year after trans-
plantation [14] and the highest incidence of CMV
infection occurs during the same period. In a recent study,
asymptomatic CMV infection was shown to affect up toticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Patient characteristics (n = 226)
Age at HTx, mean ± SD, years
Recipient (R) 45 ± 13
Donor (D) 33 ± 12
Male gender, n (%)
Recipient 176 (78)
Donor 159 (70)
Body mass index at HTx, mean ± SD kg/m2 23.8 ± 3.9
Cold ischemic time, mean ± SD minutes
CMV serology, n (%)
168 ± 49
D+ /R− 46 (20)
D+ /R+ 101 (45)
D− /R+ 64 (28)
D− /R− 15 (7)
Induction therapy, n (%)
CsA 48 (21)
ATG 165 (73)
Daclizumab 4 (2)
Prednisone 9 (4)
CAD, n (%) 73 (32)
Hypertension, n (%) 30 (13)
Diabetes Mellitus, n (%) 23 (10)
Previous smoking, n (%) 127 (56)
TRS at 1 year, mean ± SD 0.49 ± 0.30
TRS≥ 2R at 1 year, mean ± SD 0.22 ± 0.20
Table 2 Morbidity in CMV disease and asymptomatic CMV
infection related to CMV serostatus
Serostatus Number of
patients
CMV disease,
n (%)
Asymptomatic CMV
infection, n (%)
No CMV,
n (%)
D+/R− 46 30 (65) 11 (24) 5 (11)
D+/R+ 101 21 (21) 19 (19) 61 (60)
D−/R+ 64 11 (17) 12 (19) 41 (64)
D−/R− 15 2 (13) 4 (27) 9 (60)
Total 226 64 (28) 46 (20) 116 (51)
D donor; R recipient
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low with pre-emptive therapy [15]. However, the impact
of asymptomatic CMV infection on the long-term pro-
gression of CAV has not been studied.
The primary aim of our study was to investigate the
impact of asymptomatic CMV infection and CMV disease
on overall survival and CAV during long-term follow
up after heart transplantation. In addition, the study
evaluated potential predictors for CAV-free survival and
severity of CAV.
Methods
Study population
This was a retrospective, single-centre study of all patients
undergoing first heart transplantation in Gothenburg,
Sweden, between January 1988 and December 2000. Dur-
ing this period, 283 transplantations were performed in
278 patients. Of these, 34 patients died within 30 days of
transplantation and were excluded from the analysis, as
were 17 children < 14 years and one patient for whom the
record from 1988 could not be found. In 226 patients,
CMV infection, disease and potential risk factors were
evaluated during the first 12 months after transplantation.
Angiographic signs of CAV were recorded for 10 years or
until death. Cardiovascular risk-factors were monitored
according to protocol. Statins was given as universal ther-
apy after 1996. Follow-up of all patients was complete
through 31 December 2000. No patients were lost to
follow-up.
Immunosuppressive therapy
The induction therapy during 1988–1993 consisted of
cyclosporine A (CsA) and from 1994 of anti-thymocyte
globulin (ATG; 2.5 mg/kg/day administered intravenously
before surgery and for 3 to 5 days afterwards). Daclizumab
or 100 mg of prednisone was given in the event of ATG
allergy. Methylprednisolone was administered at 500 mg
intravenously before surgery and 500 mg intra-operative
and then at 125 mg every 8 hours for 3 doses during the
whole study period. The maintenance immunosuppres-
sion therapy consisted of standard triple therapy. CsA (5
to 8 mg/kg/day) was used to maintain serum CsA levels
within range 200–350 ng/ml during the first year and
from 100 to 200 ng/ml thereafter. Azathioprine (AZA)
was administered at 2 mg/kg/day, and prednisone at
0.2 mg/kg/day reduced to 0.1 mg/kg/day orally. Since
1995, Tacrolimus (TAC) was an alternative to CsA, given
at 0.075 mg/kg to maintain serum tacrolimus levels within
range 10–15 ng/ml and, since 1997, AZA was replaced by
mycophenolate mofetil (MMF) (2–3 g/day).
Detection of CMV infection
CMV infection was detected by serology (seroconversion
post-transplant), viral culture, qualitative polymerase chainreaction (PCR) for CMV DNA, histopathology and
immunohistochemistry (IHC) with CMV-specific anti-
bodies from endomyocardial biopsies (EMB) or tissue
biopsies from other organs. Clinical symptoms of CMV
disease were also documented for 12 months after
transplantation.
Definitions of CMV infection
CMV infection: CMV virus detected by viral culture or
qualitative, PCR assay for CMV in any body fluid or tissue
specimen. Seroconversion from CMV (seronegative to
seropositive) was also regarded as CMV infection.
Table 3 Incidence of CMV disease and asymptomatic CMV infection in D+/R− transplants according to era after HTx
Era Prophylaxis CMV disease, n (%) Asymptomatic CMV infection, n (%) No CMV, n (%)
1988–1991 (n = 18) No 12 (67) 5 (28) 1 (5)
1992–1997 (n = 17) Pre-emptivea 13 (76) 3 (18) 1 (6)
1998–2000 (n = 11) Universalb 5 (46) 3 (27) 3 (27)
Total (n = 46) 30 (65) 11 (24) 5 (11)
aPre-emptive treatment, monitoring with qualitative CMV PCR once weekly or two weeks apart for the first three months post-transplantation b1,000 mg of oral
ganciclovir tid for 14 weeks
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CMV infection or CMV disease.
Asymptomatic CMV infection: Evidence of CMV infec-
tion but not fulfilling criteria for CMV disease.
CMV disease: Evidence of CMV infection with attribut-
able symptoms in accordance with Ljungman et al. [16].
CMV disease was categorized as tissue-invasive disease
or CMV syndrome with fever, leucopoenia and/or
thrombocytopenia.
Prophylaxis, treatment and monitoring of CMV
All patients during 1988 to 1991: No CMV prophylaxis
was given. Patients were tested frequently. Seronegative
patients received treatment with intravenous (i.v.) ganci-
clovir or foscavir for 14–21 days in the event of serocon-
version or a positive viral culture for CMV.
High-risk group (D+/R−) during 1992 to 1997: Pre-emptive
treatment was given, comprising monitoring with qualitative
CMV PCR once weekly during the first three months
post-transplantation. When CMV DNA was detected in
serum, patients received treatment with i.v. ganciclovir
for at least 10 days. During 1998–2000, universal prophy-
laxis was given with 1,000 mg of oral ganciclovir tid for
14 weeks.
Intermediate-risk group (R+) during 1992 to 2000: No
prophylaxis was given. Qualitative CMV PCR was analyzed
in serum when CMV disease was clinically suspected.
In D+/R−transplants, serological analyses were repeated
once monthly for the first 4 months after HTx, then at
6, 9 and 12 months and thereafter annually and when
infection was suspected during 1988 to 1998.
CMV disease was treated with 5 mg/kg of i.v. ganciclo-
vir bid for 10–21 days. Asymptomatic CMV infection was
treated in seronegative recipients. Ganciclovir dosing wasTable 4 Incidence of CMV disease and asymptomatic CMV infection
Era Prophylaxis CMV disease, n (%)
1988–1991 (n = 59) No 11 (19)
1992–1997 (n = 74) Targeteda 11 (15)
1998–2000 (n = 32) Targeteda 10 (31)
Total (n = 165) 32 (19)
aTargeted prophylaxis given with 5 mg/kg of i.v. ganciclovir bid for 10 days in a
anti-rejection treatment with high-dose corticosteroids within the first 4 monthsadjusted for renal function. Patients who developed severe
CMV pneumonitis (hypoxia) also received polyclonal
immunoglobulin.
Diagnosis of CAV
All available coronary angiographic studies performed in
the study cohort between the first and tenth year of
follow up, or until death or re-transplantation, were
retrospectively re-analyzed visually. Where coronary
angiography was not performed in patients who were
alive during the study period it was due to medical
contraindications or patient refusal. CAV-free survival
was defined as the time to CAV of any grade observed
visually by angiography. CAV was graded according to
Costanzo et al. (none, mild, moderate or severe) [17]. The
severity of CAV (none, mild, moderate, severe) was assessed
throughout follow up. Donor-related coronary artery
disease was defined as no stenosis = 0 or no significant
stenosis = 1 from coronary angiographic studies performed
before HTx.
Risk factor analysis
Data on potential risk factors for CAV were collected
retrospectively, including recipient and donor charac-
teristics, cold ischemic time, cardiovascular risk factors
(hypertension, diabetes mellitus, smoking status before
transplantation and complications (acute rejection (AR)
episodes).
Surveillance endomyocardial biopsies for AR were
standardized for all patients and graded according to
the 2005 ISHLT classification as 1R, 2R or 3R [18]. AR
therapy consisted of 1,000 mg boluses of methylpredniso-
lone for 3 consecutive days in cases of AR ≥ 2R. Severe
cellular rejections were treated with 2.5 mg/kg/day ofin R+ recipients according to era after HTx
Asymptomatic CMV infection, n (%) No CMV, n (%)
8 (13) 40 (68)
17 (23) 46 (62)
6 (19) 16 (50)
31 (19) 102 (62)
ssociation with the first anti-rejection treatment with ATG and the second
post-transplantation
Johansson et al. BMC Infectious Diseases  (2015) 15:582 Page 4 of 9ATG for 3 days. Clinical relevant antibody-mediated rejec-
tion (AMR) was treated with plasmapheresis. The cu-
mulative effect of acute cellular rejection was assessed
by the total rejection score (TRS) [19] and defined as
0R = 0, 1R = 1, 2R = 2, 3R = 3. Severe TRS was defined as
all AR ≥ 2R. The scores were normalized for the total num-
ber of biopsy specimens taken during the first 12 months
after HTx (TRS or TRS ≥ 2R) in the individual patient.
Ethics
This study was approved by the local Ethical Committee
of Gothenburg (115–14) and by the medical director of
the heart transplant department at the University Hospital,
Gothenburg, Sweden. The data were recruited from the
patients’ medical records and local registries according to
standards by the Declaration of Helsinki.
Statistical analyses
Data were analyzed using SPSS version 20.0 (SPSS Inc,
Chicago, IL, US). Continuous variables are presented as
mean values ± standard deviations (SD) and categorical
variables as percentages. The chi-square test was used
to compare proportions and occurrences between groups.
Confidence intervals (CI) were calculated using a normalityFig. 1 Survival—10 years of follow-up in 226 heart transplant recipients. Surv
without CMV infection, n = 116 (69%), compared with patients with CMV dise
(54%; p = 0.053). (Patients were followed to re-transplantation (n = 5) or deathapproximation algorithm. Survival and CAV-free survival
time was analyzed using the Kaplan–Meier procedure and
statistical comparisons of survival distributions between
different categories were made using the log rank test.
Cox’s univariate and multivariate model was used to
determine risk factors for events. Variables in the uni-
variate model testing with a p value < 0.1 were included
in the multivariate model. A p value < 0.05 was consid-
ered statistically significant.Results
Patient characteristics
In total, 226 patients who received a first HTx and had
complete data regarding CMV infection during the first
post-transplant year were included in the analysis. The
baseline characteristics of recipients and donors are de-
scribed in Table 1. The main causes of death were CAV
(14 %), acute rejection (3 %) and infection (9 %). The
mean follow-up for CAV disease was 8.9 years.
Diagnosis of CMV infection or disease were performed
by seroconversion in 25 patients, qualitative CMV PCR
in 49 patients, tissue biopsies with histopathology and IHC
with CMV-specific antibodies in 19 patients, and viralival during a follow-up of 10 years was significantly higher for patients
ase, n = 64 (55%; p = 0.018), and asymptomatic CMV infection, n = 46
) Kaplan–Meier survival curve, the mean follow-up was 9.9 years
Johansson et al. BMC Infectious Diseases  (2015) 15:582 Page 5 of 9culture in 16 patients. CMV retinitis was diagnosed in
one patient by an ophthalmologist.
Incidence of CMV infection and disease
Of the 226 patients analyzed, 28 % (n = 64) developed
CMV disease (tissue invasive, 11 % (n = 26) and 17 % (n =
38) developed CMV syndrome). Asymptomatic CMV in-
fection was detected in 20 % of patients (n = 46).
In the 26 patients with tissue-invasive CMV disease,
the following manifestations were recorded; myocarditis
(n = 10), myocarditis + pneumonitis (n = 1), myocarditis +
gastrointestinal disease (n = 1), gastrointestinal disease
(n = 7), pneumonitis (n = 5), nephritis (n = 1) and retin-
itis (n = 1). The 26 cases of tissue-invasive CMV disease
were proven in 85 % of the patients (n = 22) and pos-
sible in 15 % (n = 4).
The incidences of CMV disease and asymptomatic
CMV infection according to the CMV serology status
(donor positive (D+) or negative (D−) vs recipient positive
(R+) or negative (R−)) are shown in Table 2. The onset of
CMV disease in the high risk (D+/R−) serology group
without CMV prophylaxis occurred significantly earlier
(57 (22–178) days) after transplantation compared to the
patients given oral ganciclovir for 14 weeks (103 (64–156)Fig. 2 CAV-free survival—10 years of follow-up in 226 heart transplant reci
higher for patients with no CMV infection (n =116) compared with patient
(n = 46; p = 0.013). (Patients were followed to re-transplantation (n = 5) or ddays) after transplantation (p = 0.008). There was no
significant difference in the onset of CMV disease in
the intermediate-risk serology groups (R+) without prophy-
laxis (45 (19–86) days) compared with targeted prophylaxis
(51 (17–151) days) after transplantation (p = ns).
The combined incidence of CMV disease or asymp-
tomatic CMV infection was highest in the D+/R− group
compared with the D+/R+, D−/R+ and D−/R− groups
(p < 0.001) (Table 2). When the different eras of prophy-
laxis strategy were taken into account, there was no
statistical significant difference in the incidence of
CMV disease or asymptomatic infection compared to no
CMV infection in the high risk (D+/R−) group (p = 0.08)
(Table 3) or the intermediate-risk (R+) group (p = 0.25)
(Table 4). In addition, across the total study group there
was no statistical difference between different eras in
terms of the incidence of CMV disease or asymptomatic
CMV infection (p = 0.62) at 1 year after transplantation.Survival according to CMV status
There were no significant differences in the risk for
CMV disease or asymptomatic CMV infection versus no
CMV infection according to recipient age (p = 0.537),pients. CAV-free survival during a follow-up of 10 years was significantly
s with CMV disease (n = 64; p <0.001) and asymptomatic CMV infection
eath) Kaplan–Meier curve, the mean follow-up was 8.9 years
Table 6 Multivariate analysis for risk factors associated with
CAV-free survival 10 years after Htx
Risk factor HR 95 % CI p-value
Recipient age 1.00 0.98–1.01 0.424
Donor age 1.04 1.02–1.06 <0.001
CAD 1.86 1.19–2.93 0.007
TRS≥ 2R 2.01 0.84–4.80 0.114
No CMV - - Ref.
CMV disease 1.88 1.21–2.91 0.005
CMV infection 1.75 1.11–2.77 0.017
Ref reference category when calculating HR
Table 5 Univariate analysis for risk factors associated with
CAV-free survival 10 years after Htx
Risk factor HR 95 % CI p-value
Recipient male 1.18 0.79–1.76 0.417
Recipient age 1.01 1.00–1.03 0.034
Recipient body mass index 1.03 0.99–1.08 0.137
Donor male 1.13 0.79–1.63 0.491
Donor age 1.04 1.03–1.06 <0.001
CAD 1.65 1.18–2.30 0.003
No CMV - - Ref.
CMV disease 2.03 1.39–2.95 <0.001
Asymptomatic CMV infection 1.63 1.07–2.46 0.022
Donor-related CAD 1.49 0.86–2.59 0.153
Cold ischemic time 1.00 0.99–1.00 0.518
AMR at first year 1.18 0.71–1.96 0.531
TRS 1.51 0.84–2.72 0.165
TRS≥ 2R 2.07 0.87–4.93 0.099
Hypertension 1.39 0.89–2.18 0.146
Diabetes mellitus 1.05 0.85–1.30 0.646
Ex-smoker 1.23 0.87–1.76 0.245
CMV serology
D−/R− - - -
D−/R+ 1.22 0.57–2.62 0.602
D+/R− 1.80 0.82–3.91 0.141
D+/R+ 1.50 0.72–3.12 0.278
Ref reference category when calculating HR
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0.483) or TRS ≥ 2R score at 1 year (p = 0.259).
Survival was 7.0 years (95 % CI 6.0–7.9) for patients
with CMV disease, 7.5 years (95 % CI 6.4–8.5) with
asymptomatic CMV infection and 8.7 years (95 % CI
8.2–9.2) with no CMV infection. Survival at 10 years
post-transplant (mean 9.9 years) was significantly higher
for patients without CMV infection (69 %), compared
with patients who had CMV disease (55 %; p = 0.018) or
asymptomatic CMV infection (54 %; p = 0.053) (Fig. 1).
CAV-free survival and risk factors of CAV by univariate
and multivariate analyses
A total of 1272 coronary angiographic studies performed
in 204 patients between 1 and 10 years after HTx were
re-analyzed. Twenty-two patients did not survive to the
first coronary angiography. In the last coronary angiog-
raphy performed, no CAV was found in 113 (50 %) pa-
tients, mild CAV in 40 (18 %) patients, moderate CAV
in 41 (18 %) patients and severe CAV in 10 (4 %) patients.
Sixty-four coronary angiographies were performed in do-
nors before HTx. Thirty-one patients had CAV at the first
year after HTx, of whom 6 had donor-related coronary ar-
tery disease and 8 had no lesions on angiography before
HTx. The TRS at one year was 0.49 ± 0.30 and TRS ≥ 2R
was 0.22 ± 0.20. Histologically suspected AMR was found
in 26 patients, 5 of whom received plasmapheresis and 1
underwent re-transplantation due to graft loss.
CAV-free survival for the total study population was
5.7 years (95 % CI 5.21–6.24). CAV-free survival was sig-
nificantly longer for patients without CMV infection
6.7 years (95 % CI 6.0–7.4) compared with patients with
CMV disease 4.2 years (95 % CI 3.2–5.2) (p < 0.001) or
asymptomatic CMV infection 5.4 years (95 % CI 4.3–6.4),
(p = 0.013) (Fig. 2).
Univariate analysis for potential risk factors for CAV
or death (time to first event) during 10 years follow-up
showed that recipient age, donor age, CAD, asymptom-
atic CMV infection, CMV disease and TRS ≥ 2R were
statistically associated with CAV-free survival at 10 years
(Table 5).
In a multivariate Cox-regression analysis, CMV dis-
ease, asymptomatic CMV infection, CAD and donor age
were independent predictors for CAV-free survival at
10 years after transplantation (Table 6).
There was no statistical significant difference in the grade
of CAV at 10 years according to different eras of trans-
plantation (p = 0.175) (Fig. 3) or CAV status (p = 0.81).
Discussion
The main finding of this study is that not only CMV dis-
ease but also asymptomatic CMV infection during the
first year after heart transplantation predispose patients
to develop cardiac allograft vasculopathy over the longterm. In addition, CMV disease was an independent
predictor of survival after 10 years of follow-up.
In previous reports, CMV infection has repeatedly
been shown to play an essential role in CAV progression
[9, 10, 20, 21] although several studies have not found an
association between CMV and CAV [12, 13, 22]. The rea-
sons for this discrepancy could include inadequate sample
size, short-term follow up, different diagnostic methods for
CAV and varying definition for CMV infection. Sagerdal
et al. showed that during long-term follow-up of kidney
Fig. 3 The grade of CAV according to different era after transplantation. Result of coronary angiographies showing the distribution in the grade
of CAV in the different observation periods after heart transplantation (p = 0.175). CAV, cardiac allograft vasculopathy
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tion within the first 100 days after kidney transplant-
ation were independent risk factors for major
cardiovascular events and mortality [23].
Our observations regarding the effect of CMV disease
and asymptomatic CMV infection on long-term CAV-free
survival after heart transplantation are in line with a re-
cent study by Delgado et al. [24]. In their study, CMV
infection was monitored during the first year after
transplantation and both CMV disease and asymptom-
atic CMV viremia were shown to be independent pre-
dictors for long-term development of CAV. Both our
analysis and that of Delgado et al. [24] included pa-
tients from the 1990s, when immunosuppressive treat-
ment was intensive and monitoring strategies with
limited CMV prophylaxis therapy were practised. These
results support the emerging evidence that more ag-
gressive monitoring and treatment strategies are im-
portant to prevent CMV infection. Potena et al. have
shown that in heart transplant patients managed by a
pre-emptive strategy, asymptomatic CMV infection was
associated with an increased risk of developing CAV, de-
fined as abnormal coronary remodeling 1 year after HTx
[6]. In another report from Potena et al. CAV was reduced
by the suppression of subclinical CMV infection [25], indi-
cating not only an association but also a possible causal
role for CMV in the pathogenesis of CAV. The finding
that subclinical (i.e. asymptomatic) CMV infection is as-
sociated with CAV development is also consistent withthe data showing that universal CMV prophylaxis is asso-
ciated with less intimal thickening [26].
The link between AR and CAV is controversial
[19, 24, 27–30]. Raichlin et al. showed that AR during
the first 3 to 6 months after transplantation predisposed
patients to onset of CAV [19]. Caforio et al. found that
rejection score was an independent predictor of CAV
onset, but not severity [30]. Delgado et al. also found
that severe acute cellular rejection and donor age were
independent predictors of CAV, consistent with the out-
come of our univariate analyses [24]. However, only
donor age and previous CAD remained as predictors of
CAV in our multivariate analysis.
The strength of our study is the large monocentric
study population (n = 226) and the long-term follow-up,
with CAV-free survival follow-up over a mean of 8.9 years.
A high proportion of the recipients (49 %; 110/226) were
diagnosed with CMV disease or asymptomatic CMV in-
fection, making it easier to study the long-term influence
of CMV. The same person reviewed all the medical re-
cords. A diagnosis of CMV, and CMV-related symptoms,
were carefully reviewed and re-evaluated throughout the
follow up period making the diagnosis of asymptomatic
CMV infection reliable.
Limitations are that this is a retrospective analysis of a
heterogeneous patient cohort in which different diagnos-
tic methods and prophylaxis strategies were applied dur-
ing the observation period. However, after adjustments
for the different periods after transplantation (i.e. based
Johansson et al. BMC Infectious Diseases  (2015) 15:582 Page 8 of 9on prophylaxis strategy), we found no statistical signifi-
cant differences in the incidence of CMV disease,
asymptomatic CMV infection, CAV status or grade of
CAV. In addition, a pathological diagnosis detected by
IHC with CMV-specific antibodies was available at all
times and was used more frequently than today. The
qualitative CMV PCR and, later, quantitative PCR used
in our study is more sensitive than viral culture and
seroconversion, and makes it possible to treat CMV in-
fection early, before CMV disease occurs. We might,
however, have missed some patients with asymptomatic
CMV infection since scheduled CMV screening was
only performed in the high-risk serology group during
the early part of the observation period. We did not in-
clude HLA mismatches or lipid levels as variables be-
cause of insufficient data. In a systematic review of
factors associated with CAV, lipid levels were not shown
to be associated with CAV using angiography [31]. Al-
though the coronary angiography used in our study is not
as sensitive as intravascular ultrasound, we were able to
compare our results to the most recent evidence relating
to the long-term effects of CMV infection on CAV using
angiography [24]. In addition, coronary angiographies
were frequently performed in our population and a cardi-
ologist re-evaluated and graded all coronary angiographies
according to the consensus paper of Costanzo et al. [17].
Donor-related CAD was assessed by coronary angiog-
raphy before transplantation in only a subset of the study
cohort. However, the mean age of the donors was low
(33 years). We have previously shown that selection of
donor hearts older than 40 years of age based on coronary
angiography to exclude pre-existing CAD did not reduce
the prevalence of CAD nor improved survival among
heart recipients between 1988 and 2005 [32].Conclusions
In this long-term follow up of heart transplant recipients,
CMV disease and asymptomatic CMV infection, together
with donor age and previous CAD, were independent
predictors of angiographic CAV. Our study supports emer-
ging evidence that aggressive strategies to prevent not only
CMV disease but also asymptomatic CMV infection may
be important in reducing the early and late development
of CAV. More studies are required to define the optimal
length of CMV prophylaxis and the approach, i.e. pre-
emptive vs universal prophylaxis, in order to prevent
low-viral replication of CMV.Abbreviations
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